idiopathic pulmonary fibrosis
Conditions
Interventions
disease behaviour
idiopathic pulmonary fibrosis
interstitial lung disease
pulmonary function
Sponsors
Roche Nederland B.V.
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Signed Informed Consent Form 2. Able to comply with the study protocol, in the investigator*s judgment * for example, the ability to use the provided spirometer and tablet and the ability to fill in the required patient reported outcomes questionnaires 3. Age *50 years 4. Suspicion of IPF/ILD: Radiological evidence of IPF/ILD in symptomatic patients (unexplained dyspnea on exertion and/or cough)
Exclusion criteria
Exclusion criteria: 1. Participation in any investigational study within 28 days prior to inclusion 2. History of clinically significant cardiac disease that could explain the patient*s symptomatology in the opinion of the investigator 3. Known history of any connective tissue disease, including, but not limited to, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or mixed connective tissue disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decline in Forced Vital Capacity (FVC) of patients with IPF during the peri-diagnostic period | — |
Secondary
| Measure | Time frame |
|---|---|
| Please refer to paragraph 6.4.2. in the protocol | — |
Countries
Canada, France, Ireland, Italy, Netherlands, Russian Federation, United Kingdom
Outcome results
None listed